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Abstract
Genome-wide association scans with high-throughput metabolic profiling provide unprecedented 
insights into how genetic variation influences metabolism and complex disease. Here we report 
the most comprehensive exploration of genetic loci influencing human metabolism to date, 
including 7,824 adult individuals from two European population studies. We report genome-wide 
significant associations at 145 metabolic loci and their biochemical connectivity regarding more 
than 400 metabolites in human blood. We extensively characterize the resulting in vivo blueprint 
of metabolism in human blood by integrating it with information regarding gene expression, 
heritability, overlap with known drug targets, previous association with complex disorders and 
inborn errors of metabolism. We further developed a database and web-based resources for data 
mining and results visualization. Our findings contribute to a greater understanding of the role of 
inherited variation in blood metabolic diversity, and identify potential new opportunities for 
pharmacologic development and disease understanding.
The discovery of mutations causing severe congenital metabolic disorders, or inborn errors 
of metabolism, has revolutionized our early understanding of how genes control biochemical 
reactions and metabolic pathways in the human body 1. Recent technological advances in 
metabolomics and genetics allowing the collection of high dimensional datasets in large 
population samples suggest that inborn errors of metabolism are only extreme cases of a 
wide spectrum of genetic variation in human metabolism, and that these loci are often at the 
basis of multifactorial traits and complex diseases. The so-called genetically influenced 
metabotypes (GIMs) identified to date have been shown to display larger effect sizes 
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compared to most complex trait loci 2 and map preferentially in or near genes that encode 
enzymes, metabolite transporters and regulators of metabolism 3-13.
However, while the biomedical and pharmaceutical relevance of these associations may 
become clearer as focused gene-by-gene investigations are conducted, little is known about 
their system-wide interconnectivity, and how this knowledge can be translated into medical 
practice. A comprehensive blueprint of human metabolic pathways and the genes that 
regulate them would inform strategies for modifying deregulated metabolites in a rational 
and targeted manner, potentially using already existing drugs, as has been suggested for 
other GWAS findings 14. In this context, genetic associations provide powerful tools to 
identify genes that may be targeted to modulate metabolite levels.
Here we present the most comprehensive investigation of genetic influences on human 
metabolism to date, extending previous studies based on the same metabolomic 
platform 11,15. We applied powerful hypothesis-generating genome-wide scans to survey 
regions of the genome associated with a wide range of metabolic traits. The hundreds of 
associations and their metabolic context reported in this study identify a system-wide atlas 
of molecular readouts of activity for human genes measured in vivo. We not only provide 
information on hundreds of single genotype-metabolite associations, greatly expanding 
knowledge of metabolic intermediates of gene functions and disease, but we also generate a 
network including the majority of metabolites reliably measurable in blood using the 
Metabolon platform, allowing future exploration of perturbations caused by individual 
genetic variants across hundreds of metabolites at once. Finally, this information is based on 
experimental in-vivo data from a human population study. In this respect, this work contrasts 
the classical metabolic pathway maps that are obtained as composites of single in vitro 
biochemistry experiments. The novel loci empower future clinical and pharmacologic 
research in a number of key areas, spanning from a better understanding of genetic 
predisposition to disease, to the identification of potential novel biomarkers and drug 
surveillance tools, drug targets and the causal evaluation of environmental and modifiable 
influences on human traits and disease 16. Moreover, in order to maximize the downstream 
utility of the data for the broader scientific community, we make the atlas freely available 
through an extensive suite of web resources, including a database of detailed functional 
annotations and disease associations for each locus, and a network view of the data with 
linkage to genetic and metabolic web resources (see URLs). In the following we summarize 
the key results of our study.
Results and discussion
Eighty-four novel metabolic loci
The study sample included a total of 529 metabolites profiled using liquid-phase 
chromatography and gas chromatography separation coupled with tandem mass 
spectrometry in either plasma or serum from 7,824 adult individuals from two European 
population studies (Supplementary Table 1). Of these, the entire KORA dataset (N=1,768) 
and a small proportion of the TwinsUK dataset (1,052 individuals and 250 metabolites) have 
been described in two previous studies 11,15, with 5,002 TwinsUK individuals newly 
profiled in this study. Over half of the 529 metabolites (N=333, 63%) were chemically 
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identified and could be assigned to eight broad metabolic groups (amino acid, carbohydrate, 
cofactors and vitamin, energy, lipid, nucleotide, peptide and xenobiotic metabolism) as 
described in the KEGG database 17. These groups could be further subdivided into 63 
distinct biochemical pathways. Another 196 metabolites (37%) were classified as 
‘unknown’, indicating that their chemical identity has not yet been conclusively established. 
Further information on the unknown metabolites, including measurement platform, retention 
time, m/z and fragmentation spectra can be found in Supplementary Table 2. Analyte 
overlap between unknowns and knowns was excluded using correlation analysis 
(Supplementary Table 3). After stringent quality controls, a subset of 486 metabolites was 
available for genetic analysis in both cohorts, including 309 known and 177 unknown 
metabolites.
The primary genome-wide discovery analysis was carried out on approximately 2.1 million 
single nucleotide polymorphisms (SNPs) either directly genotyped, or imputed from the 
HapMap2 panel 18, and passing stringent quality control metrics (Online Methods, 
Supplementary Figure 1). From this initial discovery effort, 137 independent variants were 
significantly associated with metabolite concentrations at a stringent genome-wide cutoff of 
1.03×10−10 (=5×10−8/486 metabolites; Supplementary Tables 4 and 5) 19. Subsequent 
discovery analysis on 98,346 pairwise metabolite ratios identified eight additional loci at a 
more stringent cutoff of 5.08×10−13 (=5×10−8/98,346 ratios; see the Supplementary Note for 
a discussion on interpretation of ratio). Overall, our study revealed 299 SNP-metabolite 
associations of genome-wide significance at 145 statistically independent SNPs 
(Supplementary Table 5, Figure 1 and Supplementary Figure 2). Of these, 84 loci have not 
been reported before, while three loci were reported while this work was in revision 20. 
Another 61 loci were identified in previous studies, thus suggesting validation across 
different platforms 2,10,11,15,21. A subset of the loci were also reported in smaller scale 
studies conducted in other tissues, suggesting that metabolite associations are reproducible 
across tissues and that blood metabolite loci may be for the most part representative of 
associations in other tissues. For instance, all five genome-wide significant loci detected in a 
study in urine in a discovery sample of 862 individuals 22 were also detected in blood in this 
study. As another example, the PYROXD2 locus was associated with an NMR metabolite in 
urine 23. The novel loci identify a rich catalog of novel metabolic associations, allowing 
URLs
• A supporting online website summarizing genetic associations and biologic and disease annotation from this study, and a 
searchable version of the metabolic network, is accessible from http://gwas.eu/si;
• A fully annotated version of the GGM network in Cytoscape format is available for download from http://
metabolomics.helmholtz-muenchen.de/gwa/si/network/SI_network.cys;
• Genome-wide association statistics are freely accessible through the Metabolomics GWAS server at http://
metabolomics.helmholtz-muenchen.de/gwas;
• Gene expression data is available from http://www.muther.ac.uk/.
• The raw metabolomic measurements can be accessed, together with the genome-wide genotype data, through application 
from the respective data access committees (http://epi.gsf.de/kora-gen/seiten/angebot_regel_e.php?page=Services and 
www.twinsuk.ac.uk/data-access)
• The Orphanet a list of all 501 genes contributing to an inborn error of metabolism can be found at http://www.orpha.net/
consor/cgi-bin/Disease_Classif.php?lng=EN&data_id=150&PatId=10507&search=Disease_Classif_Simple&new=1.
• The Citeline Pharmaprojects Pipeline can be found at http://www.citeline.com/products/pharmaprojects/.
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linkage of genetic and disease associations with underlying molecular mechanisms and 
greatly enriching understanding of the genetic control of human metabolism. We 
systematically evaluated evidence for genes within a 1-Mb window centered on the sentinel 
SNPs to identify cases where the function of the gene matches the relevant metabolite 
(Online Methods). This effort identified a plausible or established biochemical link for 101 
of the 145 loci, and involving 94 unique genes (reviewed in Supplementary Table 6). We 
henceforth refer to these 94 genes as ‘predicted causal’. For the remaining loci we annotated 
the gene nearest to the association peak.
Where a predicted causal gene was associated with a metabolite ratio, and both metabolites 
have been identified, we can characterize that ratio in terms of the underlying biochemistry. 
In eleven cases, the metabolite ratio seems to reflect the flux through a particular metabolic 
reaction that is influenced by the SNP (annotated as ‘activity’ in Supplementary Table 6). 
For instance, GOT2 (encoding mitochondrial glutamic-oxaloacetic transaminase 2) was 
associated with the ratio between phenyllactate (PLA) and phenylalanine. GOT2 catalyzes 
the conversion of phenylalanine to phenylpyruvate, which is then converted to 
phenyllactate 24. Another such example was MBOAT7, associated with the ratio of 
arachidonate (20:4n6) to 1-arachidonoylglycerophosphoinositol. MBOAT7 encodes a 
lysophosphatidylinositol acyltransferase that has specificity for arachidonoyl-CoA as an acyl 
donor 25. Arachidonate is readily converted to arachidonoyl-CoA.
In five cases both metabolites in a ratio were linked to a substrate or both linked to a product 
(for instance at ACE, SULT2A1, AKR1C4, ABP1 and THEM4). In these cases the effect of 
the genetic variant may be explained as causing one molecule to be consumed or acted on 
faster than the other (‘selectivity’).
In seven cases the levels of one metabolite ‘normalizing’ the statistical signal for the other 
may explain the ratio. For instance, PRODH encodes proline dehydrogenase, which 
catalyzes the first step in proline degradation 26. However, the p-value for the ratio of valine 
to proline was even stronger than the p-value for proline itself, suggesting that valine may be 
normalizing the proline concentration against the overall amino acid pool.
A de novo atlas of human metabolic relationships in blood
We next generated a network view of genetic-metabolic interactions in the two cohorts by 
combining genetic and metabolite information. First, we connected metabolites with 
metabolites using Gaussian graphical models (GGMs). We have previously demonstrated 
that GGMs connect biochemically related metabolites 15,27, and can be applied to 
reconstruct metabolic pathways directly from the metabolomics data. Second, we connected 
metabolites with genetic loci based on our primary GWAS results, i.e. one link for each 
genome-wide significant association. For a more detailed description of the network 
generation process, see the Supplementary Note. To verify the stability of partial correlation 
values in both cohorts, we performed a bootstrapping-based subsampling approach. We 
observe generally low standard deviations, especially for high partial correlation values, 
indicating a high stability of the estimation. The resulting network (Figure 2) recapitulates 
relationships between 397 metabolites from 60 different pathways (249 known and 148 
unknown) and 131 of the 145 genetic loci, and provides the first comprehensive and high-
Shin et al. Page 5
Nat Genet. Author manuscript; available in PMC 2014 December 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
resolution reference map of human metabolic reactions and their genetic influences 
measured in a single in vivo “experiment” in blood.
This in vivo reference map of metabolite relationships in blood complements existing 
knowledge of gene-metabolite relationships in specialized biochemical databases. It 
facilitates the visualization of genetic associations in the context of complex relationships 
between metabolites and SNPs, as in the case of the peptide sub-network of dipeptide and 
oligopeptide metabolites and peptide-related genes (Figure 2, box). To maximize the use of 
the data to the scientific community, we make the network available for download with 
extensive biochemical and biological annotation (URLs). We further make available a 
version of the network with basic annotation through a web browser, allowing rapid 
visualization and exploration of the data. Furthermore, an extensive database of genetic 
associations and their biologic, medical and pharmacologic annotation is available in 
Supplementary Table 6 and through the supporting online website (see URLs).
Allelic architecture of metabolic loci
To fully quantify the extent to which the metabolic loci capture metabolite variance, we 
carried out exhaustive characterizations of the allelic architecture of the novel loci. 
Metabolite heritabilities were estimated using the classical twin (ACE) model and the twin 
structure of the TwinsUK cohort (Figure 3, Supplementary Note). The contribution of 
metabolic loci to metabolite variance was high (median 6.9%, range 1-62%, Supplementary 
Note and Supplementary Table 7), with variants explaining greater than 20% heritability at 
approximately 10% of the metabolites and greater than 50% in four cases. This supports 
previous observations that variants explain on average greater proportions of trait variance 
for some metabolite classes compared to what is generally observed for complex traits 2, 
confirming the value of these intermediate molecular readouts for dissecting genetic 
contributions to complex traits with greater statistical power. We carried out local 
imputation with a denser haplotype reference map (1000 Genomes Project) for each of the 
145 loci to explore the contribution of additional variants with lower minor allele frequency 
present in this panel and poorly represented by HapMap2 imputation. With the exception of 
the CYP3A cluster, the two imputation panels yielded lead SNPs with highly correlated 
frequency, p-values and explained variance at most loci (Supplementary Table 8, 
Supplementary Figure 3). We further explored the contribution of SNP-SNP interactions 
between the metabolic loci, defined as a departure from additive marginal effects (Online 
Methods). The analysis suggested that the effects of metabolic loci were predominantly 
additive, apart for the statistically significant interaction observed between NAT8 and 
PYROXD2 variants 23 (Figure 4, Supplementary Figure 4, Supplementary Table 9).
Finally, we systematically compared the metabolite-associated SNPs against public 
repositories of variants (cis-eQTLs) affecting gene expression in liver 28, fat, skin and 
lymphoblastoid cell lines (LCLs) 29. For each lead metabolomic SNP, we first retrieved all 
SNPs with high linkage disequilibrium (r2≥0.8) in the 1000 Genomes Project pilot phase 
(CEU population). Each lead SNP and its proxies were then used as baits to search the two 
expression databases. A total of 57 lead SNPs identified ciseQTLs in at least one of four 
tissues searched under the nominal permutation p-value<0.001, defining a total of 101 SNP-
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gene pairs and 97 different genes (Supplementary Table 10). Of the 97 genes, 38 were 
predicted as causal based on our annotation, and 59 as non-causal. When compared to non-
causal genes, causal genes showed 3.25-fold enrichment in the liver eQTL dataset (Fisher’s 
exact test p-value = 0.023, two-tailed), possibly reflecting the greater contribution that liver 
metabolism makes to blood metabolite levels. Furthermore, causal genes were enriched by 
1.6-fold in fat compared to non-causal genes (Fisher’s exact test p-value = 0.038, two-
tailed). No enrichment was seen in LCL and skin.
One major challenge of interpreting associations from GWAS is formulating and testing 
hypotheses on the causal effect of a SNP on an associated trait. Molecular QTL studies on 
metabolite or gene expression have greater statistical power compared to more complex 
traits like for instance HDL or LDL cholesterol levels 2. In this context, testing correlations 
between SNPs, metabolite concentrations and other molecular phenotypes (for instance 
epigenetic profiles or transcript levels) provides new opportunities to investigate metabolite 
pathways at the molecular level (see also Supplementary Information). We applied 
Mendelian randomization analysis to test the hypothesis that metabolite-associated SNPs 
affected metabolites through variation in transcript levels of corresponding causal genes. We 
focused on a subset of 32 predicted causal genes that had a matching eQTL in at least one 
MuTHER tissue and exploited a subset of 484 individuals of the MuTHER dataset where 
gene expression levels were measured at the time of metabolomic measurement (Online 
Methods). Such analysis revealed two loci significant at the Bonferroni-corrected p-
value<1.5×10−3, namely THEM4 and CYP3A5. In both cases the allele associated with 
increased metabolite levels was associated with decreased gene expression in one or more 
tissues (Figure 4, Supplementary Table 11). This analysis provides support for the 
underlying causal variants having regulatory consequences for these two loci.
Biological relevance
The novel associations span the large majority of the metabolic pathways explored, 
indicating widespread genetic influences on the human metabolome. We could assign a 
known biochemical function to approximately two-thirds of the overall associations (101 out 
of the 145 loci, Supplementary Table 6). One third (N=34) of the novel loci involved amino 
acids, and a similar number (N=33) were with intermediates of lipid metabolism, including 
notably sterols, carnitines and intermediates of inositol and fatty acid metabolism. The 
remaining novel associations were across a wide range of metabolic classes and functions, 
including importantly pathways with a central role in cellular metabolism and energy, 
intermediates of purine and pyrimidine metabolism, glucose homeostasis and vitamins and 
cofactor levels among others. In cases where a metabolite is of unknown identity, the 
metabolic function of the associated gene provides an hypothesis on its identity, as described 
earlier 15.
The current characterization of hundreds of loci embedded in their metabolic context further 
allows exploration of complex systems to a significantly greater depth and breadth 
compared to previous studies 2,10,11,15,21. For instance, 12 novel associations were within 
phenylalanine, tyrosine and tryptophan metabolism pathways, implicated in key brain 
functions through dopamine and serotonin biosynthesis. Among them, two common variants 
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in TDO2 (encoding tryptophan 2,3-dioxygenase) and IDO1 (encoding indoleamine 2,3-
dioxygenase 1) were associated with tryptophan and 4-hydroxytryptophan (X-12100) 
respectively, two intermediates of synthesis of the neurotransmitter serotonin. Several loci 
mapped to transporters, including association of plasma tyrosine and tryptophan levels with 
SLC16A10 (encoding a T-type amino acid transporter 1 (TAT1) for tryptophan, tyrosine and 
phenylalanine 30), associations between plasma kynurenine levels and SLC7A5 (encoding 
LAT1), which mediates cellular exchange of tryptophan and the tryptophan metabolite 
kynurenine 31, and many others. It will be important to characterize whether these 
associations provide reliable molecular readouts for the function of these genes in the brain, 
to ascertain the value of accessible tissues such as blood to dissect genetic influences on 
systems that are not readily accessible in vivo. As shown with this example, all associations 
in this study can now be used in a similar manner to explore other disease-relevant 
connections. Finally, we note that metabolomics analysis in blood reflects a cumulative 
readout of processes that occur in different metabolically active tissues, including uptake, 
release, production, and disposal of biochemicals from individual organs. Thus whether one 
of the genetic variants that we report here has an effect in a specific tissue will depend on 
whether the respective protein is actually expressed and active in that tissue. It is possible, 
and even likely, that analyses in individual tissues will show even more distinct metabolic 
profiles and stronger genetic associations than those observed here. A greater 
characterization of patterns of tissue specificity for metabolite levels and associations will be 
necessary to address this question.
Disease and pharmacological relevance
Integration of metabolic associations with complex traits and disease empowers 
understanding of molecular underpinnings of disease, as shown in the case of the 
bradykinin/kininogen/kinin system and cardiovascular disease (Supplementary Figure 5 and 
Supplementary Information). We searched the NHGRI GWAS Catalog (July 2013) for cases 
where the sentinel SNP either matched a complex trait or disease variant or was in high 
linkage disequilibrium with one (defined as r2≥0.8, Online Methods). A total of 41 
metabolite-associated SNPs (Supplementary Table 4) and 14 out of 84 novel, matched SNPs 
previously associated with complex disease or drug response endpoints (Figure 5, 
Supplementary Table 4). We further searched the 1-Mb intervals centered on the associated 
SNP for genes causative for inborn errors of metabolism, identifying a significant 
enrichment (26 cases, hypergeometric test P-value = 5.9×10−16; Supplementary Table 12). 
As recently postulated by Mootha and Hirschhorn 32, this suggests that several genes 
(including CPS1 UGT1A1, CBS and SLC22A4-5 and others) harbor genetic variants with 
effects ranging from loss-of-function alleles in metabolic disorders all the way to common 
polymorphisms with moderate phenotypic consequences in multifactorial complex diseases 
and finally quantitative variation in the ‘normal’ range. One such example was the CPS1 
locus, encoding a mitochondrial carbamoyl phosphate synthetase, an enzyme catalyzing the 
generation of carbamoyl phosphate from ammonia and bicarbonate. Mutations in CPS1 
cause carbamyl phosphate synthetase deficiency, an autosomal recessive disorder 
characterized by congenital hyperammonemia and defective citrulline synthesis. A common 
variant in CPS1 was previously associated with increased risk of chronic kidney disease 33. 
The same variant was associated with glycine levels in this and previous studies 10,34,35. 
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Glycine is interconverted to ammonia via the glycine cleavage complex 36, and provides a 
molecular intermediate trait for the disease.
The extension of clinical chemistry analysis to a richer set of metabolites in this study, and 
the underlying linkage to genetic differences, further present important novel opportunities 
to identify variants of possible pharmacogenomic relevance and new pharmacologic targets. 
Among the 132 unique genes associated with the 145 metabolic loci, 56 (42%) identify 
genes of potential interest for pharmacological development. Of them, 24 (18%) were drug 
targets (10 genes), drug-metabolizing enzymes (11) or transporters (3) for FDA- and/or 
EMA-approved drugs. For instance, 45 different FDA-approved drugs with a broad range of 
indications were linked with the ten drug targets alone (Supplementary Table 13). A further 
11 genes were drug targets with compounds in early to late stages of development (from pre-
clinical to Phase I, II and III and to registration) and 24 genes were linked to drugs that are 
either suspended, discontinued or have no reported development activity (Supplementary 
Table 14). Thus, overall 21 of the 132 (16%) reported genes were either established or 
promising drug targets. This indicates that druggable targets are highly enriched within 
metabolomic loci (2.8-fold enrichment, Chi-squared test P-value=1.19×10−5) when 
compared to the estimated druggable fraction of human genes (1,089 of 19,258 human 
genes, or 5.6% 14). Finally, 21 additional genes are targets, drug metabolizing enzymes or 
transporters for bioactive drug-like compounds (Supplementary Table 6). In these and other 
cases, the metabolic associations and linkage to disease status identifies possible new 
therapeutic targets concordant with biomarkers for clear establishment of efficacy, and may 
inform patient stratification based on genetic profiling. Furthermore the associated 
metabolites identify potential biomarkers that are readily detectable in accessible samples, 
for example urine or plasma, and that may improve evaluation of disease or efficacy of new 
medicines while accounting for individual genetic background. Finally, this catalogue of 
associations provides important new opportunities for drug repositioning or the 
identification of novel indications for existing drugs, thus potentially unlocking some of the 
original investment.
Conclusions
In summary, we carried out the most comprehensive analysis of genetic influences on 
human blood metabolites to date. Our observations suggest widespread genetic control over 
a large range of different pathways and functions, and support the notion of human 
metabolism as a complex continuum governed by genetic effects of variable intensity, 
complex regulatory influences and non-genetic effects. Our results advance knowledge in a 
number of areas of biomedical and pharmacogenetic interest, generating nearly one hundred 
novel hypotheses of SNP-metabolite and disease correlates and identifying a large catalog of 
novel potential biomarkers as well as associations to drug targets, transporters and metabolic 
enzymes. Lastly, the network provides a comprehensive in vivo reference map of genetic 
influences on blood metabolites in a healthy human population sample, linking genetic 
variants to hundreds of biochemical relationships and pathways. The data and results 
generated by this study are made freely available through a web database and a 
downloadable network to facilitate the necessary functional and clinical exploration of these 
novel hypotheses.
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Online Methods
Study Samples
The TwinsUK cohort is an adult twin British registry composed of mostly women aged 18 to 
102. These twins were recruited from the general UK population through national media 
campaigns and shown to have similar disease-related and lifestyle characteristics to 
population-based singletons in the same age group 37. The samples used in this study are 
93% female in the age range 17 to 85 (mean 53 years). The Cooperative Health Research in 
the Region of Augsburg (KORA) study is a series of independent population-based 
epidemiological surveys and follow-up studies of participants living in the region of 
Augsburg, Southern Germany 38 The present study includes data of the follow-up study 
KORA F4 (2006–2008) of the KORA S4 survey (1999/2000). Individuals were aged 
between 32 to 77 years (mean 61 years) and had equal numbers of males and females 
(Supplementary Table 1). All participants in both TwinsUK and KORA have given written 
informed consent and the local ethics committees, Guy’s and St. Thomas’ Hospital Ethics 
Committee for TwinsUK, and Bayerische Landesärztekammer for KORA, approved the 
studies.
Data analysis
Primary genome-wide association analysis for metabolites
Genome-wide association: The primary association testing was carried out at each SNP (in 
the HapMap2 based imputed genotype dataset) for all 486 metabolite concentrations present 
in both TwinsUK and KORA datasets after QC steps. Linear regression models (assuming 
an additive genetic model) were used. Age and sex were included as covariates in both 
cohorts. Additionally, batch effect (described above in Metabolomics data acquisition and 
pre-processing) was added to the model only in TwinsUK, since the 1,768 KORA F4 
individuals were processed in a single batch. In TwinsUK, associations were carried out 
using the MERLIN software 39. Briefly, MERLIN is based on the variance-component 
regression model and provides two family-based association tests under multivariate 
normality assumptions: a likelihood ratio test and a score test. In contrast to recently 
developed linear-mixed-model-based programs that estimate individual relationships from 
genotypes, MERLIN takes pedigree information from direct input of family pedigrees and 
reported twin status (monozygotic or dizygotic). Association tests were run on best guess 
genotypes (where genotypes were called if they had a posterior probability >0.9) using the 
computationally more efficient score test. In KORA, linear models were fit for unrelated 
individuals using the software QUICKTEST 40. Briefly, QUICKTEST is based on 
maximum likelihood estimation and assesses association tests for unrelated individuals 
under the linear model framework with the assumption of normal mixture model for the 
error distribution. QUICKTEST can deal with uncertain genotypes (for example, imputed 
genotypes with uncertain scores) and non-normal trait (for example, traits with skewness 
and heavy tails). Association tests were carried out on allelic dosages (0-2) accounting for 
uncertainty in imputed genotypes. For the 145 most associated SNP-metabolite pairs, 
associations were recalculated in TwinsUK using allelic dosage to ensure that association 
results were not affected by the genotype modeling. The resulting association P-values were 
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virtually identical to those obtained from MERLIN (R2=0.99), demonstrating that there was 
no bias associated with the use of best-guess genotypes in TwinsUK and allelic dosages in 
KORA.
Meta-analysis: Association results in TwinsUK and KORA were combined using inverse 
variance meta-analysis based on effect size estimates and standard errors adjusting for 
genomic control. Heterogeneity in each association between datasets was tested using 
Cochran’s Q test (which is equivalent to McNemar test here as the number of datasets is 
two). All above analyses were carried out using the METAL software 41. To control for 
false positive error rates deriving from the large number of SNPs tested, a conservative 
Bonferroni adjusted p-value of p=1.03×10−10 (=5×10−8/486) was applied for declaring 
genome-wide significance for the SNP-metabolite associations. SNPs with low imputation 
quality (info<0.4), low minor allele frequency (<0.01), significant heterogeneity of effects 
between the two cohorts (defined as heterogeneity p<0.001 and p-value in either cohort 
being ≥0.001=0.05/486) or present in only one cohort were removed after meta-analysis. A 
lead SNP at each locus was selected to be the SNP with the lowest p-value against any trait 
at that locus. For each metabolite, all associations passing this cutoff were assigned to 
independent loci by iteratively allocating the lead SNP with the lowest p-value and SNPs 
within 500kb away from it into the same locus. These assignments were further revised as 
described later to estimate the effective number of independent loci.
Genome-wide analysis of metabolite/metabolite ratios—A second discovery step 
was carried out by testing genome-wide associations on all 98,346 (=444*443/2) pairwise 
ratios of two metabolite concentrations present in both cohorts after QC steps, following the 
principle described previously 11. Xenobiotic metabolites were excluded due to the low 
average call rates per individual. Due to the high number of traits and computation time and 
costs, for metabolite ratios genome-wide analyses were carried out in the TwinsUK study 
alone, followed by replication of significant hits (Bonferroni corrected 
p<5.08×10−13=5×10−8/98,346) in KORA F4. SNPs with low MAF (<1%) and info (<0.4) 
were removed from analysis, as in the association analysis on single metabolites. From the 
analysis in TwinsUK, a total of 430 loci survived Bonferroni correction and only the top 
association for each locus (i.e. the metabolite ratio and the SNP pair with the lowest p-value) 
was carried forward for replication in KORA. Both discovery and replication results were 
meta-analysed using the inverse variance model, and the combined result was filtered again 
on Bonferroni adjusted p-value of p<5.08×10−13 and heterogeneity (p≥0.001). Further notes 
on the interpretation and reporting of ratios are provided in the Supplementary Note.
Refinement of independence at metabolite loci—A series of additional analyses 
were carried out to further refine the identity of single metabolite- and metabolite ratio-
associated loci. These analyses were aimed at identifying (i) loci where secondary, 
independent association signals map to less than 500kb from each other, or (ii) non-
independent signals spanning >500kb owing to long-range linkage disequilibrium (LD). As 
a first step, the lead SNPs from analysis of metabolite concentrations and ratios were pooled. 
Regional association plots were created for each locus and trait, and were visually inspected 
to identify possible independent signals within each locus, or to detect possible signals 
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spanning two consecutive loci. For these loci where putative independent SNPs were 
identified (defined as the two SNPs having an r2≤0.5 in the 1000 Genomes CEU 
population), conditional analyses were used to assess statistical independence between two 
loci. Specifically, we tested reciprocally association with each SNP while adding the second 
SNP as a term in the linear model. A Bonferroni correction for the number of pairs tested 
was applied to declare significance for the conditional test p-value. In case of non-
independence, the best SNP-metabolite pair with the lowest association p-value was 
reported at each locus.
Total heritability estimates—The genetic and environmental influences on 503 single 
metabolites present in TwinsUK after QC steps were inferred by two common methods. 
First, the correlations of monozygotic and dizygotic twin pairs under the ACE model (which 
models trait variance as a function of additive genetics, common environment and unique 
environment and/or error effects) were compared, and narrow-sense heritabilities were 
inferred from the proportion of the total variance explained by estimated additive genetic 
effect. To estimate parameters of ACE model, a maximum likelihood method was applied 
under multivariate normality assumptions using the OpenMx software 42 adjusting for age, 
sex and batch effects (Supplementary Table 7). Metabolites measured in fewer than 30 twin 
pairs (either monozygotic or dizygotic) were excluded from calculations for heritability 
estimation.
Known heritability estimates under additive models—Next, the known heritability 
was estimated for 170 single metabolites associated with genetic variants in our GWAS. The 
explained genetic variance of each metabolite was estimated by multiple regression analysis 
including all associated SNPs under additive genetic models, after adjusting for covariates 
(age and sex in KORA; age, sex and experimental batch effect in TwinsUK). Only unrelated 
twin individuals were used for the analysis to avoid biases due to familial correlation. The 
known heritability was defined as the ratio of total variance of the metabolite to the variance 
explained by the multiple regression models including all SNPs significantly associated with 
the metabolite. This known heritability was then compared with the total heritability inferred 
above (Supplementary Table 7).
Imputation using denser haplotype maps from the 1000 Genomes Project—
Genetic variants associated with metabolite concentrations below the genome-wide 
significance cutoff may contain true signals contributing to metabolite heritability. To 
survey more comprehensively genetic variation at the 145 metabolic loci, the associations at 
each locus were recalculated following imputation using a denser reference set (1000 
Genomes Project, 1KGP) 43. Genome-wide genotypes were imputed using the 1KGP multi-
population panel (March 2012 release for TwinsUK; June 2011 release for KORA), and 
associations with metabolites were tested as described before within a 1Mb window 
centered on each lead SNP. The analyses were carried out in TwinsUK and KORA 
separately and the results were combined by inverse variance meta-analysis following the 
procedure used in the HapMap2-based GWAS. Then, minor allele frequency, association p-
value and the variances explained by two models (Y=α+β×SNP1KG+ε and Y=α
+β×SNPHM2+ε) were compared between the most associated SNPs identified in the 
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HapMap2- and 1GK-based imputations (respectively SNPHM2 and SNP1KG). Finally, the 
explained genetic variance of each metabolite was estimated by multiple regression analysis 
including all associated SNPs1KG under additive genetic model, and compared with the total 
heritability and with the known heritability estimated above using the original lead SNPs 
(referred as SNPsHM2 above). Overall, at 80% of the loci the 1KG-based imputation yielded 
a different variant compared to the HM2 imputation used for discovery (Supplementary 
Table 8). However, the 1KG lead SNPs had similar minor allele frequency (R2=0.85), 
association p-value (R2=0.99) and explained variance (R2=0.96) to the HM2 SNPs 
(Supplementary Figure 3 a-c), with only one locus (CYP3A4/5) showing a significant 
improvement in association in the 1KGP dataset (Supplementary Figure 3 d,e).
Epistatic interactions in known heritability estimates—Frequent statistical 
interaction (epistasis) between genetic variants have been proposed to inflate heritability 
estimates by creating so-called phantom-heritability 44. While exhaustively testing 
interactions between SNPs genome-wide at all traits would be statistically intractable, it is 
nevertheless of interest to explore possible epistatic effects between genome-wide 
significant SNPs, particularly given their co-occurrence within tight metabolic networks. For 
the test for epistasis, we focused on all pairs of SNPs associated with the same metabolite at 
genome-wide significance (106 pairs of SNPs associated with 51 metabolites; 
Supplementary Table 9). The SNP-SNP interaction was defined as a departure from additive 
marginal effects and verified by ANOVA F-test comparing two models below with and 
without an interaction term:
and
The same covariates used in the primary discovery effort (age and sex in KORA; age, sex 
and batch in TwinsUK) were included in each model. For simplicity, in TwinsUK only 
unrelated individuals were included in the analysis. A Bonferroni corrected p-value of 
p=0.00047 (=0.05/106) was applied to declare significant epistasis. These tests revealed no 
evidence for interaction among the associated loci (P≤4.7×10−4 (=0.05/106)), suggesting a 
lack of strong interaction effects among the loci tested. Exceptions were variants at two loci 
(rs10469966 at NAT8 and rs4488133 at PYROXD2), for which a significant interaction was 
observed on metabolite X-12093 in TwinsUK (ANOVA F-test P=1.63×10−5), replicated in 
KORA (P=5.71×10−11, Figure 4, Supplementary Figure 4). Fitting the interaction model 
yielded a modest increase in explained trait variance compared to the additive model 
(R2INT=15.6% vs R2ADD=14.4% in TwinsUK; R2 =27.7% vs R2 INT ADD=24.2% in 
KORA).
Bioinformatic annotation of genes at metabolite loci—The 1,968 protein coding 
genes within 500 kb of any of the lead SNPs were systematically annotated to identify cases 
where the gene function could be linked biochemically to the associated metabolite 
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(‘predicted causal genes’). First, each gene was annotated for its distance and linkage to the 
lead SNPs. A graph-based method was used to find potential paths from each gene to the 
linked metabolites with edges derived from the data in KEGG 17 and EHMN 45. 
Comprehensive text mining was then used to identify all PubMed abstracts mentioning a 
synonym of the gene and a synonym of the linked metabolite(s). The assembled evidence 
was then reviewed locus by locus. Possible causal genes at each locus were carefully 
reviewed in BRENDA 46 and in the primary literature, and the gene with highest functional 
plausibility was selected based on the preponderance of the evidence. Because of the rich 
literature in biochemistry and enzymology going back at least four decades, predicted causal 
genes could be identified for the vast majority of the loci with known metabolites. Where a 
predicted causal gene was not identified, the locus was annotated with the gene nearest to 
the metabolite-associated SNP.
Annotation of genes for inborn errors of metabolism—To annotate overlap with 
genes causative for inborn errors of metabolism, we retrieved from Orphanet (see URLs) a 
list of all 501 genes contributing to an “inborn error of metabolism” and compared it to the 
list of all genes contained within the 500kb flanking each of the 145 lead SNP. Of the 501 
genes, 26 are in our list of 94 predicted causal genes. Against a background of 19,297 
protein-coding genes, this corresponds to a highly significant enrichment (hypergeometric 
test p-value = 5.9×10−16). This is in fact the strongest p-value for any “branch” or subgroup 
within the Orphanet ontology.
Annotation of variants mapping to complex trait and disease loci—In order to 
identify cases where the metabolomic-associated SNPs had evidence for previous 
association with complex traits and diseases, we first retrieved all variant from the 1000 
Genomes Project Pilot 1 having high linkage disequilibrium with the 145 sentinel SNPs 
(defined by r2≥0.8 in the CEU sample). These variants were then compared against the 
NHGRI GWAS Catalog (July 2013 release) with the search set to all available traits and 
diseases. These cases were annotated in Supplementary Table 4 and Supplementary Table 6 
in the field “Complex trait association [PMID]”. Cases where the variant matched a 
metabolic trait association using the same rule were annotated in the “Metabolite association 
[PMID]” field, also in Supplementary Table 6.
Annotation of variants mapping to expression QTLs—A thorough analysis of the 
eQTL signals at the lead SNPs was conducted as follows. For each lead metabolomic SNP, 
we first retrieved all SNPs with high linkage disequilibrium (r2≥0.8) in the 1000 Genomes 
pilot phase (CEU population). Each lead SNP and its proxies were then used as baits to 
search the MuTHER Project expression database 29 and a published liver eQTL dataset 28. 
All significant cis-eQTLs within a 1Mb window centered on the lead SNP were retrieved 
from these dataset, and the best eQTL p-value in each tissue was noted. A total of 57 lead 
SNPs identified cis-eQTLs in at least one of three tissues searched under the nominal or 
permutation p-value<0.001 (Supplementary Table 10). For additional information see the 
Supplementary Information.
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Mendelian randomization analysis on causal metabolite pathways—The relative 
normalized gene expression values for all eQTLs identified in the previous paragraph were 
retrieved for 484 unrelated TwinsUK participants with available genotype data, and with 
gene expression and metabolite data were measured at the same time point by the MuTHER 
project 29 in three tissues (fat, skin and lymphoblastoid cell lines or LCL).
Mendelian randomization 47 analysis was used to test the hypothesis that changes in 
expression levels (GE) would cause metabolite level changes (MET), using genotype of the 
lead SNP as an instrumental variable. The causal effect from GE to MET was estimated by 
the Wald ratio method 16 as the ratio of SNP effects (i.e. instrumental variable effects) on 
GE and MET as follows:
where  is the coefficient for the linear regression model of MET on SNP, and 
 is the coefficient for the linear regression model of GE on SNP. The covariate 
adjustments (age, sex and batch effects for MET; age, sex and probe batches for GE) were 
made prior to analysis. To test the causal effect of 32 lead SNPs of the loci where annotated 
causal genes overlap with MuTHER eQTLs, a Bonferroni corrected 99.85% confidence 
interval (~=1-0.05/32) for the causal effect from GE to MET was obtained from 10,000 
permutations, and the null hypothesis on no causation was rejected if the confidence interval 
did not cross zero (Supplementary Table 11).
Drug associations—A list of approved drugs by the Food and Drug Administration 
(FDA) and/or the European Medicines Agency (EMA) was retrieved from the ChEMBL 
database 48. A total of 132 unique genes reported in Supplementary Table 4, and including 
either predicted causal genes (94 unique genes) or genes nearest to the associated SNP, were 
considered. Genes were classified as drug efficacy targets (DT), metabolising enzymes (ME) 
and/or transporters (TP) according with their role in clinical pharmacology. For the genes 
classified as drug targets, the therapeutic annotation was extracted from the current version 
of the approved prescribing information, summary of product characteristics (SPC) and the 
primary literature. For the genes classified as metabolizing enzymes and transporters, the 
annotation was compiled from the information present in 49,50. The mapping of Uniprot IDs 
to gene locus was retrieved from ENSEMBL Biomart, release 70 51, and the mapping of 
Uniprot IDs to ChEMBL IDs from ChEMBL14 48.
Further mapping of the 132 genes to drugs was also conducted using Citeline 
Pharmaprojects Pipeline (see URLs, accessed on July 1, 2013) to annotate targets for drugs 
in other stages of development. For each metabolic locus, Pipeline was searched using the 
metabolic locus’ gene symbol as search criteria for the Biological Target field. From the 
search results, information gathered was the drug’s name, and the drug’s global status of 
drug development. Entries for drug targets corresponding to launched drugs were checked 
for consistency against the previous set of FDA- and/or EMA-approved drugs, and 
information was retained from the initial set. Only information for drug targets 
corresponding to the following categories was retained from this latter dataset (excluding 
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‘launched’): (i) In development (preclinical, Phase I, Phase II, Phase III, pre-registration, 
registration); (ii) no development (suspended, withdrawn, no development reported).
A full description of Methods used in this study is available in the Supplementary Note.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Ideogram of metabolomic associations
Chromosomal map illustrating the location of the 145 loci identified in this study. Locus 
label colors are indicative of metabolite pathway class for the strongest associated 
metabolite at each locus, and are carried through additional figures and in the corresponding 
Cytoscape file (see URLs). An interactive web version of this figure at the supporting online 
website (see URLs) provides an entry point to biologic and functional annotation for each 
locus.
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Figure 2. A network view of genetic and metabolic associations
The network view was built by combining genetic associations with a GGM network created 
from metabolite concentrations. A. Each node represents either a set of metabolites 
belonging to the same pathway (circular nodes) or a genetic locus (diamond-shaped nodes). 
An edge between a pathway and a locus was drawn if at least one metabolite showed a 
genome-wide significant association with the locus. A line between two pathway nodes was 
drawn if there was at least one connection in the underlying metabolite GGM network 
between two metabolites of the respective pathways (see Online Methods). Node color keys 
are the same as in Figure 1. Numbers within metabolite loci indicate pathway name as 
detailed in the legend. Numbers associated with each pathway name indicate the number of 
metabolites contained within each pathway node. B. Example of a network with full-detail 
resolution. The network is provided in digital form for interactive viewing at the supporting 
online website (see URLs). The fully annotated network is also available for download in 
Cytoscape format from the same website.
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Figure 3. Heritability and variance explained
We used the ACE model to partition the variance of each metabolite into narrow-sense 
heritability (orange), and common (purple) and unique environmental components. The 
proportion of heritability explained by all SNPs associated with a given metabolite at the 
genome-wide level is shown in red. The corresponding numeric values for heritability 
estimates are given in Supplementary Table 7.
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Figure 4. Epistatic effects and Mendelian randomization analyses on eQTL loci
(A) Interaction between NAT8 and PYROXD2 variants. Levels of the metabolite X-12093 
are plotted as a function of genotypes at the two variants rs10469966 (NAT8) and rs4488133 
(PYROXD2), showing a significant SNP*SNP interaction on metabolite levels. See also 
Supplementary Figure 4. (B) Regional plots illustrating overlap of association of SNPs with 
metabolites (red) and gene expression levels measured in fat (black), skin (blue) and LCLs 
(green) at locus 11. Associations p-values (–log10 scale) are plotted for a 1 Mb window 
surrounding the lead SNP rs6693388, and for associations of the SNP with linoleate 
(18:2n6)/ 5,8-tetradecadienoate (red), and with THEM4 expression in fat (black), skin (blue) 
and LCL (green) respectively. (C) Example of relationships tested by Mendelian 
randomization analysis at the same locus, where expression of gene THEM4 is shown to 
mediate the association between rs6693388 and the ratio linoleate (18:2n6) to 5,8-
tetradecadienoate. All analyses were done in a subset of 484 unrelated TwinsUK participants 
with gene expression measured at the same time of visit of metabolomic measurements. The 
full results are in Supplementary Table 11.
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Figure 5. Medical and pharmacological relevance of metabolomic associations
Genes reported in Supplementary Table 4 were classified based on their overlap with inborn 
errors of metabolism, or for being targets, metabolizing enzymes or transporters of FDA-
approved drugs. Variants were annotated based on their overlap with complex trait and 
disease loci. Novel associations reported for the first time in this study are highlighted in 
bold. The symbols dev and b identify genes associated with compounds in active stages of 
drug development (preclinical, Phase I-III, pre-registration to registration) and bioactive 
drug-like compounds respectively. Full details on locus annotation are provided in 
Supplementary Tables 6, 13 and 14 and in the full version available on the supporting online 
website (see URLs).
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